PhaseBio Pharmaceuticals, Inc.
PHAS · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $11 | $320 | $2,361 | $668 |
| % Growth | -96.6% | -86.4% | 253.4% | – |
| Cost of Goods Sold | $0 | $320 | $0 | $0 |
| Gross Profit | $11 | $0 | $2,361 | $668 |
| % Margin | 100% | 0.1% | 100% | 100% |
| R&D Expenses | $102 | $72,088 | $30,911 | $15,455 |
| G&A Expenses | $16 | $13,088 | $11,186 | $4,857 |
| SG&A Expenses | $16 | $13,088 | $11,186 | $4,857 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $118 | $85,176 | $42,097 | $20,312 |
| Operating Income | -$130 | -$84,856 | -$39,736 | -$19,644 |
| % Margin | -1,204.1% | -26,517.5% | -1,683% | -2,940.7% |
| Other Income/Exp. Net | $1 | -$13,709 | $489 | -$4,202 |
| Pre-Tax Income | -$129 | -$98,565 | -$39,247 | -$23,846 |
| Tax Expense | $2 | $0 | $0 | $0 |
| Net Income | -$131 | -$98,565 | -$39,247 | -$23,846 |
| % Margin | -1,210.1% | -30,801.6% | -1,662.3% | -3,569.8% |
| EPS | -0.005 | -3.39 | -1.43 | -4.49 |
| % Growth | 99.9% | -137.1% | 68.2% | – |
| EPS Diluted | -0.005 | -3.39 | -1.43 | -4.49 |
| Weighted Avg Shares Out | 29,398 | 29,056 | 27,494 | 5,305 |
| Weighted Avg Shares Out Dil | 29,398 | 29,056 | 27,494 | 5,305 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $237 | $1,582 | $387 |
| Interest Expense | -$1 | $1,445 | $1,076 | $3,924 |
| Depreciation & Amortization | $1,793 | $508 | $174 | $105 |
| EBITDA | $1,663 | -$96,612 | -$37,997 | -$19,817 |
| % Margin | 15,350.2% | -30,191.3% | -1,609.4% | -2,966.6% |